Cellular Biomedicine enters into definitive agreement to acquire CD40LGVAX Vaccine
The per share price will be based on the 20-day volume weighted average price (VWAP) of the Company’s Common Stock upon the closing of the acquisition. CBMG will
Daiichi Sankyo has entered a collaboration with France-based Waiv, which aims to lead digital pathology biomarker discovery for an antibody-drug conjugate (ADC) programme.
The second successfully out-licensed biosimilar in the product pipeline is ABY-021, which is a humanized monoclonal antibody for treating immunological symptoms. The out-licensing partner is once again a